Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.

Roger M Lyons, Richard A. Larson, MD, Michael A. Kosmo, MD, Sunil Gandhi, Delong Liu, MD, PhD, Marc Chernoff, Luke Dreisbach, MD, Carmen Matei, Kuolong Hu, PhD, Janet L. Franklin, MD, MPH, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 1770.

https://doi.org/10.1182/blood.V114.22.1770.1770

Published: 2009

Journal Articles

Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.

David J Kuter, MD, DPhil, Mathias J Rummel, MD, PhD, Ralph Vincent Boccia, MD, B. Gail Macik, MD, Ingrid Pabinger, Dominik L.D. Selleslag, MD, Francesco Rodeghiero, Beng H Chong, MBBS, PhD, H. Müller-Beiβenhirtz, Lara Gehl, Xuena Wang, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 679.

https://doi.org/10.1182/blood.V114.22.679.679

Published: 2009

Journal Articles

Home Administration of Romiplostim by Patients with Chronic Immune Thrombocytopenia (ITP).

Roger M Lyons, Ralph V. Boccia, MD, Gail Macik, MD, Romeo A. Mandanas, MD, FACP, Xuena Wang, Richard Lizambri, MD, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 3510.

https://doi.org/10.1182/blood.V114.22.3510.3510

Published: 2009

Journal Articles

An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS).

Pierre Fenaux, Hagop Kantarjian, MD, Roger Lyons, Richard A. Larson, MD, Mikkael A. Sekeres, MD, MS, Pamela S. Becker, MD, PhD, Petra Muus, MD, PhD, Kuolong Hu, PhD, Dietmar Berger, MD, PhD, Janet L. Franklin, MD, MPH

Blood (2009) 114 (22): 2765.

https://doi.org/10.1182/blood.V114.22.2765.2765

Published: 2009

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim in Children with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP).

George R. Buchanan, MD, Lisa Bomgaars, MD, James B. Bussel, MD, Diane J. Nugent, MD, David J. Gnarra, MD, Victor S Blanchette, FRCP, Kun Nie, Melissa Eisen, MD, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 680.

https://doi.org/10.1182/blood.V114.22.680.680

Published: 2009

Journal Articles

Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.

James B. Bussel, MD, David J Kuter, MD, DPhil, Adrian Newland, MD, FRCP, Joost TM de Wolf, MD, Jeffrey Wasser, MD, Paul Chang, Kun Nie, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 681.

https://doi.org/10.1182/blood.V114.22.681.681

Published: 2009

Journal Articles

Self-Injection of Romiplostim by Patients with Chronic Immune Throbocytopenic Purpura (ITP)

James George, MD, James B Bussel, MD, Roger M Lyons, MD, Vinod Pullarkat, MD, Robert Redner, MD, Deirdra Terrell, PhD, Kun Nie, PhD, Dietmar Berger, MD, PhD

Blood (2008) 112 (11): 4707.

https://doi.org/10.1182/blood.V112.11.4707.4707

Published: 2008

Journal Articles

Evaluation of Bleeding and Thrombotic Events during Long-Term Use of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura.

Michael Tarantino, MD, Usha Sunkara, MD, James George, MD, Louis M. Aledort, MD, Matthew Guo, PhD, Dietmar Berger, MD, PhD, Terry Gernsheimer, MD

Blood (2008) 112 (11): 3422.

https://doi.org/10.1182/blood.V112.11.3422.3422

Published: 2008

Journal Articles

Low Immunogenicity to Romiplostim in Clinical Studies with ITP Subjects.

Vibha Jawa, PhD, Martha Hokom, Jenny Hu, Yao Zhuang, PhD, Dietmar Berger, MD, PhD, Shalini Gupta, PhD, Steven Swanson, PhD, Naren Chirmule, PhD

Blood (2008) 112 (11): 3425.

https://doi.org/10.1182/blood.V112.11.3425.3425

Published: 2008

Journal Articles

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study

David J Kuter, MD, DPhil, James B Bussel, MD, Adrian Newland, MD, FRCP, Joost TM de Wolf, MD, Troy Guthrie, MD, Jeffrey Wasser, MD, Lara Gehl, Kun Nie, PhD, Dietmar Berger, MD, PhD

Blood (2008) 112 (11): 402.

https://doi.org/10.1182/blood.V112.11.402.402

Published: 2008

Journal Articles

No Difference in Survival or Long-Term Disease Outcomes in Palifermin-Treated Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation.

Ricardo Spielberger, MD, Mary Territo, MD, Simon Durrant, MD, Stephen Nimer, MD, John McCarty, MD, David Hurd, MD, Dietmar Berger, MD, Jeff Aycock, Mon-Gy Chen, Patrick Stiff, MD

Blood (2007) 110 (11): 1664.

https://doi.org/10.1182/blood.V110.11.1664.1664

Published: 2007

NARROW

Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.

Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.

Home Administration of Romiplostim by Patients with Chronic Immune Thrombocytopenia (ITP).

An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS).

A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim in Children with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP).

Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.

Self-Injection of Romiplostim by Patients with Chronic Immune Throbocytopenic Purpura (ITP)

Evaluation of Bleeding and Thrombotic Events during Long-Term Use of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura.

Low Immunogenicity to Romiplostim in Clinical Studies with ITP Subjects.

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study

No Difference in Survival or Long-Term Disease Outcomes in Palifermin-Treated Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only